Gonadorelin
Synthetic GnRH
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
Gonadorelin is the natural GnRH decapeptide, and its pulsatile-pump use for ovulation induction in hypothalamic amenorrhea and for spermatogenesis in congenital hypogonadotropic hypogonadism carries decades of clinical data, including cohort live-birth rates around 66 to 94 percent and comparative trials against gonadotropin therapy, which supports a moderate grade for those specific hypothalamic and diagnostic indications. The use that TRT clinics now promote, injecting gonadorelin to preserve testicular function during exogenous testosterone, is off-label and unapproved, and it rests on mechanism and clinic observation rather than controlled trials, so that halo is graded lower than the legitimate reproductive-endocrinology signal.
- FDA
- Formerly FDA-approved as Factrel (diagnostic) and Lutrepulse (pulsatile ovulation-induction therapy); both discontinued for commercial reasons; no FDA-approved product currently marketed in the US, available only via 503A/503B compounding by prescription.
- WADA
- Prohibited (S2), in males only, in and out of competition
Reference only. Not medical advice.
What can go wrong
Continuous (non-pulsatile) exposure desensitizes the pituitary and suppresses gonadotropins, the opposite of the intended effect; physiologic use requires pulsatile dosing, and the off-label TRT-adjunct use is unapproved.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Gonadorelin. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
Gonadorelin is the natural GnRH decapeptide. It was formerly FDA-approved as Factrel for pituitary diagnostic testing and as Lutrepulse for pulsatile ovulation induction, both now discontinued in the US, so it is available only through compounding. Men's TRT clinics now use it off-label, injecting it to keep the testes stimulated during testosterone therapy, an unapproved application that the clinics themselves acknowledge has a limited controlled-trial base.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Gonadorelin is the body’s own GnRH, the hormone at the very top of the reproductive axis. Given in pulses, it binds the pituitary and triggers release of LH and FSH, which then drive the testes or ovaries to make testosterone or estrogen and to support sperm or egg production. The crucial detail is that it must be pulsed: intermittent dosing stimulates the pituitary, but continuous exposure desensitizes it and paradoxically shuts the whole axis down, the very trick used by GnRH-agonist cancer drugs. Its very short half-life suits this on-off, pulsed signaling.
Gonadorelin is a synthetic decapeptide, ten amino acids, identical to endogenous gonadotropin-releasing hormone (GnRH). It is the actual hypothalamic hormone rather than merely an analog, which is part of why it behaves so much like the body’s natural signal. Its half-life is only minutes, matching the body’s normal habit of releasing GnRH in pulses roughly every couple of hours.
- Type
- GnRH decapeptide
- Action
- Pituitary LH/FSH release
- Dosing
- Must be pulsed
- Half-life
- Minutes
- History
- Approved, then withdrawn
- WADA
- Prohibited
An hCG Stand-In, On Extrapolated Evidence
Gonadorelin is a real hormone caught in a market story. The compound itself is legitimate, synthetic GnRH with a genuine if now-lapsed FDA history for diagnosis and for inducing ovulation, and a sound mechanism. Its current popularity, though, is overwhelmingly in men’s testosterone therapy, to preserve testicular size and fertility, and the honest context matters: that use surged largely because compounded hCG, the long-standing and better-evidenced option for the job, became legally unavailable after a 2020 FDA enforcement action, and gonadorelin became the most-used substitute. But the TRT-preservation use is an extrapolation, not a directly studied indication: the real clinical evidence is for pulsatile-pump GnRH in diagnosed hypogonadotropic conditions, not for the subcutaneous compounded injections used as a TRT adjunct, and direct trial evidence in TRT patients is limited. There is also a mechanistic wrinkle: gonadorelin needs a responsive pituitary, yet TRT is suppressing that pituitary, whereas hCG sidesteps the problem by acting directly on the testes. It is banned in sport.
Safety in detail
Historically well tolerated in supervised diagnostic and pulsatile-pump use. The current men's-clinic use during TRT is off-label and compounded, so product quality and dosing rest on the prescribing clinic and pharmacy rather than an FDA-approved label.
- It is generally well tolerated and has a very short half-life.
- It must be dosed in pulses under clinician management; continuous or mistimed dosing can suppress the axis rather than stimulate it.
- Its dominant TRT use rests on limited direct evidence and assumes a pituitary responsive enough to react, which testosterone therapy is actively suppressing.
- It does stimulate FSH, a potential fertility advantage over hCG.
- There is no currently approved product, so it is compounded and quality-variable, and it is banned in sport.
Children and teenagers
Gonadorelin’s approved uses were adult, and while pulsatile GnRH has specialist pediatric-endocrinology uses for certain pubertal and hypogonadotropic conditions, the TRT, fertility and optimization uses have no pediatric application. Gray-market use in minors has no place. Any pediatric reproductive-axis therapy belongs strictly with pediatric endocrinologists.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Gonadorelin’s economy runs through compounding pharmacies and the booming men’s-health and TRT clinic sector, where it became the default testicular-preservation add-on after compounded hCG was restricted. Its original diagnostic and fertility brands were withdrawn. The commercial dynamic is unusual: a real hormone’s popularity was driven less by new evidence than by the disappearance of its better-studied competitor, with clinic marketing often presenting it as an upgrade rather than a substitute.
How we got here
Gonadorelin is a synthetic form of the body's native gonadotropin-releasing hormone (GnRH), the decapeptide that signals the pituitary to release LH and FSH. It was marketed in the United States as Factrel for diagnostic testing and as Lutrepulse for pulsatile fertility therapy, but both products have since been discontinued and no FDA-approved gonadorelin remains commercially available. Today it is supplied mainly through 503A compounding pharmacies and has become common in men's TRT clinics to help preserve testicular function.
Gonadorelin, synthetic GnRH, followed the identification of the hormone that governs reproduction, and it gained FDA approval for HPG-axis diagnostic testing as Factrel and for pulsatile ovulation induction. Those branded products were later withdrawn. Its modern surge came indirectly: when a 2020 FDA enforcement action made compounded hCG, the standard add-on for preserving testicular function during testosterone therapy, largely unavailable, clinicians turned to compounded gonadorelin as the most practical substitute, and it rapidly became a fixture of men’s-health and TRT practice, despite limited direct evidence for that specific use.
- pastGonadorelin is approved for HPG-axis diagnosis (Factrel) and pulsatile ovulation induction.
- laterThe branded products are withdrawn, leaving no approved product.
- 2020An FDA action makes compounded hCG largely unavailable.
- 2020sCompounded gonadorelin becomes the main hCG substitute in TRT practice.
- 2026Widely used off-label for testicular and fertility preservation, on extrapolated evidence.
The numbers behind the grade
- Type
- GnRH decapeptide
- Action
- Pituitary LH/FSH
- Approved history
- Yes, then withdrawn
- Now
- Compounded, off-label
- TRT evidence
- Extrapolated
- WADA
- Prohibited
The people taking it
A real reproductive hormone, synthetic GnRH, now hugely popular off-label in men’s TRT as a testicular- and fertility-preservation agent, largely because compounded hCG became unavailable, though its TRT evidence is extrapolated.
Gonadorelin’s users are overwhelmingly men on testosterone replacement therapy seeking to preserve testicular size and fertility, along with men specifically focused on maintaining sperm production while on testosterone, and the broader hormone-optimization crowd. Historically its population was diagnostic and fertility patients. The current audience is largely TRT-clinic-driven and male.
Historically approved for HPG-axis diagnostics and ovulation induction, now compounded mainly for off-label testicular and fertility preservation during TRT. A real hormone with a sound mechanism but extrapolated evidence for its dominant use.
Set against the alternatives
The essential comparison is to hCG. hCG mimics LH directly at the testes, bypassing the pituitary entirely, so it works even when testosterone therapy has suppressed the pituitary, and it has substantial controlled-trial data for preserving testicular function and fertility. Gonadorelin works upstream at the pituitary, giving a more complete and natural signal that includes FSH, a real fertility advantage, but it needs a responsive pituitary, must be pulsed, and has limited direct TRT evidence, and its surge owes much to hCG simply becoming unavailable. Against SERMs like enclomiphene, which raise LH and FSH by blocking estrogen feedback, it is another route to the same goal. And against long-acting GnRH agonists used to suppress the axis in cancer, it is the same molecule dosed the opposite way, a reminder of why pulsatility is everything. Its strength is a natural, complete signal; its weakness is borrowed evidence.
What we do not know
- Whether subcutaneous gonadorelin preserves testicular function and fertility during TRT as well as hCG does.
- Whether a pituitary suppressed by testosterone responds to it adequately.
- What the optimal pulsatile dosing actually is.
- Whether it is genuinely better than hCG or simply more available.
What could change
TRT-adjunct trialsThe key need is direct evidence for gonadorelin as a TRT testicular-preservation agent.hCG availabilityIts role is closely tied to whether hCG remains restricted or returns.Men’s-health growthIts use rides the rapid expansion of TRT and hormone-optimization clinics.Fertility preservationIts FSH stimulation keeps it of interest where sperm production matters.
Legal status
Gonadorelin was FDA-approved as Factrel for HPG-axis diagnosis and as a pulsatile therapy for ovulation induction, but no approved product is currently marketed, so it is used compounded. Its dominant use today is off-label, to preserve testicular function and fertility during testosterone therapy. It requires clinician-managed pulsatile dosing and is banned in sport.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Gonadorelin is obtained compounded, by prescription, mainly through men’s-health and TRT clinics, with clinician-managed dosing because pulsatility matters. Anyone using it for testicular or fertility preservation should understand the evidence is extrapolated, that hCG has more direct data for that purpose, and that it is banned in sport.
Compounded gonadorelin is moderately priced and usually obtained through TRT clinics. Its economics are tied to the restriction of compounded hCG, which it largely replaced. There is no approved branded product to price against.
Most gonadorelin comes from compounding pharmacies that filled the gap left by restricted hCG, with research and gray-market material as lower-quality alternatives. There is no currently approved product, so source quality varies.
Compounding pharmaciesThe main source since hCG restrictions, supplying gonadorelin for off-label TRT use.Men’s-health clinicsDistribute it as a testicular- and fertility-preservation add-on to testosterone therapy.Research and gray-marketLower-quality material outside the clinical pathway.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Gonadorelin.
Nothing outstanding on this one.
Sources
Gonadorelin was FDA-approved as Factrel (diagnostic, NDA 018123) and Lutrepulse/Lutrepulse Kit (pulsatile ovulation-induction therapy, NDA 019687), both since discontinued for commercial rather than safety or efficacy reasons; no FDA-approved product is currently marketed in the US.
Pulsatile GnRH administration is an effective, established treatment for central anovulation of hypothalamic origin and for male hypogonadotropic hypogonadism, reflecting a physiologic-replacement paradigm.
In a 25-year cohort, pulsatile GnRH for functional hypothalamic amenorrhea produced monofollicular ovulation with high cumulative live-birth rates, with reported live-birth rate around 66 percent per treatment.
Pulsatile GnRH in functional hypothalamic amenorrhea: 25-year cohort (PMC9790838)
A pulsatile gonadorelin pump induced earlier spermatogenesis than cyclical gonadotropin therapy in men with congenital hypogonadotropic hypogonadism, a comparative controlled clinical study.
A multicenter, double-blind, randomized, placebo-controlled study evaluated subcutaneous pulsatile GnRH via pump for ovulation induction in women with hypogonadotropic hypogonadism (Lutrepulse-related program).
ClinicalTrials.gov / LutrePulse Hypogonadotropic Hypogonadism protocol (NCT01976728)
A trial evaluated efficacy and safety of pulsatile GnRH pump treatment in patients with idiopathic hypogonadotropic hypogonadism.
ClinicalTrials.gov, Pulsatile GnRH Pump in Idiopathic Hypogonadotropic Hypogonadism (NCT02310074)
Gonadorelin (GnRH) and GnRH agonist analogs are prohibited under WADA category S2, in males only, in and out of competition, listed since 1 January 2016.
WADA S2 Peptide Hormones, Growth Factors and Related Substances (via Drugs.com)
Compounding pharmacies market gonadorelin for men's health and position it as an adjunct during testosterone therapy to support testicular function; the clinic literature attributes this use to off-label practice, not FDA approval.
TRT clinics describe gonadorelin as an off-label, widely practiced option that replaced compounded hCG after 2020 regulatory changes, while noting the controlled-trial base for the TRT-adjunct indication is limited.
Gonadorelin has a very short half-life of roughly 2 to 10 minutes, which is why physiologic effect requires pulsatile delivery and continuous exposure instead causes pituitary desensitization.
The studies that matter
Historical FDA approvalspast
Approved as Factrel for HPG-axis diagnostic testing and as a pulsatile therapy for inducing ovulation in women with hypothalamic amenorrhea.
Pulsatile-pump GnRH evidenceestablished
In diagnosed hypogonadotropic conditions, pulsatile pump-delivered GnRH can produce testicular growth and hormone production, the real evidence base from which TRT use is extrapolated.
hCG enforcement action2020
An FDA action made compounded hCG largely unavailable, prompting clinicians to adopt compounded gonadorelin as the main substitute.
TRT-adjunct evidence2020s
Direct controlled-trial evidence for subcutaneous gonadorelin as a TRT adjunct to preserve testicular function is limited; the use is an extrapolation.
hCG comparison dataestablished
hCG, which acts directly on the testes, has substantial controlled-trial data for maintaining testicular function and fertility during TRT.